Chimeric Therapeutics (CHM: $0.002) has reported stable disease now in all four patients in Cohort 2 of its CAR-T therapy in solid tumours.
Patients in the second cohort have received three times the dose (150 million cells) to the patients in Cohort 1. Three of the patients in the second cohort have colorectal cancer, and one patient has neuroendocrine tumours. One patient in the first cohort with colorectal cancer continues to have stable disease one year after the single treatment with Chimeric's therapy, CHM CDH17.
Chimeric is currently conducting a Phase I/II study in patients with solid tumours, with up to 15 patients to be enrolled in Phase I. Cells for the final two patients in Cohort 2 (9 and 10) have been prepared.
Recruitment of patients into the study has not been difficult, with many patients wanting to be involved, according to Chimeric CEO Rebecca McQualter. McQualter said that the therapy has also seen tumour shrinkage, a sign of activity, at what may still be a low dose, which is a positive sign. Cohort 3 is expected to explore a higher dose.
All patients entering the study are at Stage IV with metastatic disease, having failed multiple lines of therapy. The patient with colorectal cancer who remains stable after one year had failed four lines of chemotherapy.
The next stage, Phase II, will optimise dose and patient selection.
In the company's other program with its allogeneic CORE NK technology, the Phase Ib study has been halted temporarily as the company waits for trial material. The study is expected to resume shortly.
Chimeric Therapeutics is capitalised at $6.5 million. It held cash of just $2.4 million at the end of September.
Bioshares recommendation: Speculative Hold Class B
Disclaimer:
Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: 1AD, ACR, AVR, CGS, CUV, CYC, DXB, IMM, LBT, MX1, OPT, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than $100 are not disclosed.